Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.17 Til Enterprise Value: 1.57 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 92/100

Amgen Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 16, 2021 / 06:30PM GMT
Release Date Price: HK$1850
Jay Olson
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

Hello, everyone, and welcome to Oppenheimer's 31st Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer. And I want to thank you all for joining us. It's my pleasure to welcome Amgen to our conference and it's an honor to introduce Arvind Sood, Head of Investor Relations; Rob Lenz, Head of Global Development; and David Reese, Head of R&D.

We're really excited about all the progress at Amgen, and appreciate the opportunity to catch up with you today. So thank you for participating in our conference.

And with that, I'll turn it over to you, Arvind.

Arvind Sood
Amgen Inc. - VP of IR

Great. Thank you, Jay. Good morning, good afternoon, everybody. Hey, Jay, thank you for inviting us to your conference. I will briefly touch on some broad issues, and we can then jump into some specific R&D topics with Dave and Rob. So I've been thinking, Jay, about the one question you had raised previously, which is what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot